Many companies were screened out because performance has faltered or because of limited history. Read the full lists below at BioHealthInvestor.com:
- Outlook 2011: ARIA, CHTP, CYCC, ENMD, EXAS, EXEL, FOLD, IDIX
- Outlook 2011, Part II: AMRN, ILMN, INHX, JAZZ, NBIX, NPSP, THRX, VPHM
Stocks covered above in detail at BioHealthInvestor.com are ARIAD Pharmaceuticals Inc. (NASDAQ: ARIA), Chelsea Therapeutics International Ltd. (NASDAQ: CHTP), Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC), EntreMed Inc. (NASDAQ: ENMD), Exact Sciences Corporation (NASDAQ: EXAS), Exelixis, Inc. (NASDAQ: EXEL), Amicus Therapeutics, Inc. (NASDAQ: FOLD), Idenix Pharmaceuticals Inc. (NASDAQ: IDIX), Amarin Corporation plc (NASDAQ: AMRN), Illumina Inc. (NASDAQ: ILMN), Inhibitex Inc. (NASDAQ: INHX), Jazz Pharmaceuticals, Inc. (NASDAQ: JAZZ), Neurocrine Biosciences Inc. (NASDAQ: NBIX), NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), Theravance Inc. (NASDAQ: THRX), and ViroPharma Inc. (NASDAQ: VPHM).
You can also see the same sort of search from 2009 for the 2010 outlook that was done at BioHealthInvestor.com.
JON C. OGG